The FURI Study: Patient Outcomes After Treatment with Oral Ibrexafungerp Based on Prior Antifungal Therapy and Patient Enrollment Criteria
Oliver Cornely, M.D. (Cologne, Germany)
ECCMID, April 2022
Oliver Cornely, M.D. (Cologne, Germany)
ECCMID, April 2022
Oliver Cornely, M.D. (Cologne, Germany)
ECCMID, April 2022
R.S. Siebert, M.D. (Pretoria, South Africa)
ECCMID, April 2022
BD Alexander, OA Cornely, PG Pappas, R Miller, M Johnson, J Vazquez, L Ostrosky-Zeichner, A Spec, R Rautemaa-Richardson, R Krause, GR Thompson, TJ Walsh, CG Morse, JW Sanders, D Andes, GM Lyon, FM Marty, MH Miceli, TF Patterson, M Hoenigl, N Azie, DA Angulo
ID Week
October 2020